Hledání v detailu akcií
Moje portfolio
Nastavit Oblíbené, nastavit Portfolio
Oblíbené tituly
select
NázevNejlepší
nákup
Nejlepší
prodej
Změna
(%)
ČEZ0,00
KB-0,59
PKN60,9560,98-0,67
Msft434,53434,61-0,15
Nokia3,75053,7995-0,41
IBM216,25216,381,06
Mercedes-Benz Group AG57,5357,550,77
PFE29,8729,880,17
18.09.2024 21:31:52
Indexy online
AD Index online
select
AD Index online
 

  • 03.03.2020 23:19:58
PharmaRoth Labs (US Other OTC (Pink Sheets))
Závěr k 20.8.2024 Změna (%) Změna (USD) Objem obchodů (ks)
0,00 -17,50 0,00 11 774 481
R - Real-Time data si mohou aktivovat klienti Patria Plus / Investor Plus ZDE.

 
  • Poslední aktualizace: 18.09.2024
Popis společnosti
Obecné informace
Název společnostiPharmaRoth Labs Inc
TickerROTH
Kmenové akcie:Ordinary Shares
RICROTH.PK
ISIN-
Poslední známé roční výsledky30.06.2010
Poslední známé čtvrtletní výsledky31.03.2011
Počet zaměstnanců k 30.06.2010 0
Akcie v oběhu k 13.04.2018 394 014 970
Počet akcionářů k 30.06.2010 14
MěnaUSD
Kontaktní informace
Ulice10325 Falls Church Ave
MěstoLAS VEGAS
PSČ89144-1238
ZeměUnited States
Kontatní osoba 
Funkce kontaktní osoby 
Telefon12 125 416 222

Business Summary: PharmaRoth Labs, Inc. is a nutraceutical company. The Company is focused on diabetes prevention and treatments. The Company is engaged in marketing and selling nutraceutical drugs. The Company is engaged in the production, marketing and distribution of Sucanon, which is a clinically tested herbal-based nutraceutical treatment for Type-II diabetes. Sucanon is a member of a class of diabetic medications called insulin sensitizers. Sucanon helps the body to use its own insulin. Sucanon transports sugar out of the blood stream and into cells where it can be burned. Sucanon helps muscle cells use insulin and thus draw sugar out of the blood stream. Clinical studies have shown that Sucanon reduces blood sugar readings by 25% to 30% and brings high blood sugar into normal range. Clinical studies have shown that Sucanon reduces fatigue. Clinical studies have also shown that Sucanon reduces excess thirst and excess urination.
Financial Summary: BRIEF: For the nine months ended 31 March 2011, PharmaRoth Labs Inc revenues increased from $0K to $200K. Net loss increased from $15K to $383K. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Higher net loss reflects Professional fees increase from $0K to $210K (expense), Interest expense increase from $0K to $8K (expense).
Odvětvová klasifikace
TRBC2012Pharmaceuticals - NEC
RBSS2004Pharmaceuticals - Generic & Specialty
MGINDUSTRYBiotechnology & Drugs
MGSECTORHealthcare
NAICSPharmaceutical Preparation Manufacturing
NAICSResearch and Development in the Physical, Engineering, and Life Sciences
SICBusiness Services, Nec
SICPharmaceutical Preparations
SICCommercial Physical Research



  • Poslední aktualizace: 18.09.2024
Management společnosti
FunkceJménoVěkVe funkci odVe firmě od
Chairman of the Board, President, Chief Executive Officer, Chief Operating OfficerLuis Lopez-12.07.201231.08.2011
Interim Chief Financial OfficerBarry Hall-22.01.201322.01.2013